Covaxin, the first COVID-19 vaccine developed in India, is highly efficacious and presents no safety concerns, according to a study published in the medical journal Lancet.
Covaxin gained emergency approval from the World Health Organization recently, the eighth jab to be given the green light by the health body. The vaccine has already been cleared for use in 17 countries. Known by the code BBV152, Covaxin is an inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology.
Some of the other approved vaccines must be stored at very low temperatures, which throws up logistical and cost problems. The WHO has described it as “extremely suitable for low- and middle-income countries due to easy storage requirements”. The Indian-developed vaccine has a 78 percent efficacy rate after two doses over a month, according to the WHO.